As the AHA and its members continue to address maternal mortality, the association today voiced support for the Joint Commission’s recently proposed standards for perinatal safety. “Specifically, we support the Joint Commission’s focus on evidence-based procedures and responses that will ensure the most medically appropriate and effective course of treatment for those individuals diagnosed with either maternal hemorrhages or severe hypertension/preeclampsia,” AHA wrote. “In addition, we support the proposed requirement for education of staff, and believe conducting complication-specific training and drills will better prepare providers to act effectively and efficiently when these situations arise. Further, we support the proposed provisions to provide patients and their families with the necessary educational materials to recognize symptoms that require immediate care as another important safeguard in this process.” For more on how hospitals are working to advance better health for mothers and babies, visit https://www.aha.org/better-health-for-mothers-and-babies.

Related News Articles

Headline
Beth Heinz, senior vice president, Women’s and Children’s Services at Yale New Haven Health, and Cheri Johnson, chief nursing officer, Woman’s Hospital in…
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…
Blog
One of our best strategies to address the unique behavioral health challenges and demands of pregnant women and new mothers is recognizing that mental health…
Headline
Rep. Robin Kelly, D-Ill., member of the Health Subcommittee of the Energy and Commerce Committee and chair of the Congressional Black Caucus Health Braintrust…
Headline
The U.S. has had 935 confirmed cases of measles so far this year, according to the latest data from the Centers for Disease Control and Prevention. Cases have…
Headline
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…